Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARB | P10826 | 7/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | RARA | P10276 | 1/20 | 0.41 |
| ▸ | MTOR | P42345 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | PLA2G4B | P0C869 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | APEX1 | P27695 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Terephthalic Acid SCHEMBL2944670 | 0.69 | RARB (0.68) | RARBMEN1ALDH1A1MAPTKMT2A | |
| Terephthalic Acid SCHEMBL1884274 | 0.69 | RARB (0.68) | RARBMEN1ALDH1A1MAPTKMT2A | |
| Terephthalic Acid SCHEMBL27433040 | 0.69 | RARB (0.64) | RARBMEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL181230 | 0.68 | RARB (0.89) | RARBMEN1ALDH1A1MAPTKMT2A | |
| Terephthalic Acid SCHEMBL28142960 | 0.67 | TP53 (0.71) | RARBMEN1ALDH1A1MAPTKMT2A | |
| Dodecane SCHEMBL9354416 | 0.67 | TP53 (0.71) | RARBMEN1ALDH1A1MAPTKMT2A | |
| Terephthalic Acid SCHEMBL28103847 | 0.67 | RARB (0.66) | RARBMEN1ALDH1A1MAPTKMT2A | |
| Tetradecane SCHEMBL30605685 | 0.67 | TP53 (0.71) | RARBMEN1ALDH1A1MAPTKMT2A | |
| Terephthalic Acid SCHEMBL28502502 | 0.67 | TP53 (0.71) | RARBMEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL5448932 | 0.67 | RARB (0.86) | RARBMEN1ALDH1A1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6624309-B1 | Administering 4-heterocyclicbenzamide derivative | BRISTOL-MYERS SQUIBB COMPANY | 2003-09-23 | — | — | US | disclosed |
| US-20020137968-A1 | Benzoic acid derivatives and related compounds as antiarrhythmic agents | LLOYD JOHN (US) | 2002-09-26 | — | — | US | disclosed |
| WO-1998037068-A1 | BENZOIC ACID DERIVATIVES AND RELATED COMPOUNDS AS ANTIARRHYTHMIC AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1998-08-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020137968-A1 | Benzoic acid derivatives and related compounds as antiarrhythmic agents | SCN1A, SCN1B, NR0B1 | RARB 630/4885MEN1 2374/4885ALDH1A1 171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.